- Home
- EPIX vs EQ Comparison
EPIX vs EQ Comparison
Compare EPIX & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPIX
- EQ
- Stock Information
- Founded
- EPIX 2009
- EQ 2017
- Country
- EPIX Canada
- EQ United States
- Employees
- EPIX N/A
- EQ N/A
- Industry
- EPIX Biotechnology: Pharmaceutical Preparations
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- EPIX Health Care
- EQ Health Care
- Exchange
- EPIX Nasdaq
- EQ Nasdaq
- Market Cap
- EPIX 75.9M
- EQ 67.9M
- IPO Year
- EPIX N/A
- EQ 2018
- Fundamental
- Price
- EPIX $0.24
- EQ $1.88
- Analyst Decision
- EPIX Hold
- EQ Hold
- Analyst Count
- EPIX 3
- EQ 2
- Target Price
- EPIX $2.00
- EQ $1.00
- AVG Volume (30 Days)
- EPIX 14.7M
- EQ 16.1M
- Earning Date
- EPIX 08-13-2025
- EQ 08-14-2025
- Dividend Yield
- EPIX N/A
- EQ N/A
- EPS Growth
- EPIX N/A
- EQ N/A
- EPS
- EPIX N/A
- EQ N/A
- Revenue
- EPIX N/A
- EQ $16,553,000.00
- Revenue This Year
- EPIX N/A
- EQ N/A
- Revenue Next Year
- EPIX N/A
- EQ N/A
- P/E Ratio
- EPIX N/A
- EQ N/A
- Revenue Growth
- EPIX N/A
- EQ N/A
- 52 Week Low
- EPIX $0.22
- EQ $0.27
- 52 Week High
- EPIX $7.88
- EQ $2.35
- Technical
- Relative Strength Index (RSI)
- EPIX 6.03
- EQ 68.96
- Support Level
- EPIX $0.23
- EQ $1.50
- Resistance Level
- EPIX $0.26
- EQ $2.35
- Average True Range (ATR)
- EPIX 0.02
- EQ 0.35
- MACD
- EPIX -0.09
- EQ -0.00
- Stochastic Oscillator
- EPIX 0.87
- EQ 62.10
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.